NASH

[Nature Reviews Gastroenterology & Hepatology] The authors provide an overview of the contribution of metabolomics and lipidomics in clinical studies to identify biomarkers associated with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis.

[Scientific Reports] Researchers investigated the association of telomere length with the histological severity of non-alcoholic fatty liver disease (NAFLD). Telomere length measured from liver tissues showed a strong negative correlation with age, regardless of NAFLD status.

[Terns Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Terns Pharmaceuticals, Inc. announced the completion of patient enrollment of Part 1 of the AVIATION Trial, a Phase Ib clinical trial evaluating TERN-201, an orally-administered, highly selective inhibitor of vascular adhesion protein-1 (VAP-1), in patients with non-alcoholic steatohepatitis (NASH).

[Inventiva] Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses and other diseases, announced the initiation of its NATiV3 Phase III clinical trial evaluating lanifibranor for the treatment of NASH.

[Scientific Reports] Scientists analyzed the effect of obesity on advanced glycation endproducts (AGEs) accumulation, AGE-receptors and AGE-detoxification, and whether the absence of RAGE may have improved hepatosteatosis and inflammation, by comparing the liver of lean control, obese and obese RAGE-deficient mice.

[Clinical therapeutics] The authors summarize the emerging and more established therapeutic options considering the complex pathophysiology of nonalcoholic fatty liver disease and the important long-term sequelae of this condition.